On air · 1 of 3 networks
Siegfried
- siegfried.ch
- CH
- 2,320 employees
Siegfried’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 35. Watch Siegfried with Starter to get each new one in your feed.
Watchlist with Starter · $49/mo
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksOct 2026 | Checked | Next step |
|---|---|---|---|---|---|
| Running | 3 | Checked 29 Oct 2026 | See all 35 ads → | ||
| Meta | Not checked | — | |||
| Recently | 45 | Ads on the Google Ads Transparency Center | Checked 9 Oct 2026 | Collect them with the API → |
Siegfried has 3 live LinkedIn ads. We recorded 45 Google ads on 9 Oct 2026.
Latest ads
- LINKEDIN · JOBSince 17 Sept 2026
- LINKEDIN · IMAGESince 28 Aug 2026
Learn how to make CMC development more efficient from the research stage onward. Dr. Markus Weigandt, Global Head Drug Product R&D at Siegfried, will share practical approaches for: ✓ Early developability assessment ✓ Targeted Drug Substance investments ✓ Fit-for-purpose formulations ✓ Parallel development ✓ Platform technologies ✓ Strategic CDMO partnerships Get actionable insights you can apply to your own development programs. 📅 September 9 | 4 PM CET / 10 AM EDT
- LINKEDIN · IMAGESince 28 Aug 2026
Join Siegfried’s expert in a webinar to learn how to prioritize experiments, design scalable processes early, and connect drug substance and drug product strategies. You’ll leave with practical frameworks you can apply immediately to strengthen your CMC plan and avoid costly rework.
- LINKEDIN · IMAGESince 28 Aug 2026
CMC decisions made early can have a major impact on clinical timelines. Discover practical approaches to early developability assessment, Drug Substance strategy, formulation development and parallel execution — and learn how to accelerate development without compromising scientific rigor. Join Siegfried’s Dr. Markus Weigandt on September 9. 📅 4 PM CET / 10 AM EDT | 45 min
- LINKEDIN · IMAGESince 28 Aug 2026
Accelerating an oral drug candidate into the clinic is not simply about moving faster. Early CMC involvement, targeted Drug Substance investments and fit-for-purpose formulation strategies can help reduce rework, manage risk and shorten timelines to Phase I and Phase II. Join Dr. Markus Weigandt, Global Head Drug Product R&D at Siegfried, for a practical 45-minute webinar. 📅 September 9 | 4 PM CET / 10 AM EDT
- LINKEDIN · IMAGESince 28 Aug 2026
How can pharmaceutical development teams reduce unnecessary work and accelerate oral drug product development? In this webinar, Dr. Markus Weigandt will explore how early CMC engagement, strategic Drug Substance decisions, fit-for-purpose formulation and smarter development execution can support faster clinical progression. 📅 September 9 🕓 4 PM CET / 10 AM EDT
6 of 35 adsSign up to see every Siegfried ad, filter by format and date, and get alerts on new ones.
See all 35 adsWatch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.